会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • Inventory replication based upon order fulfillment rates
    • 基于订单履行率的库存复制
    • US20100241269A1
    • 2010-09-23
    • US12800759
    • 2010-05-22
    • Peter HamBoris KlotsRadhakrishna HariFranklin R. KoenigGautam BhargavaGerry Perham
    • Peter HamBoris KlotsRadhakrishna HariFranklin R. KoenigGautam BhargavaGerry Perham
    • G06F19/00G06F7/00G06Q10/00G06Q30/00
    • G06Q10/087G06Q10/06315G06Q10/06375G06Q30/0201G06Q30/0601G06Q30/0617G06Q30/0633
    • A load balancing technology segregates various inventory types (e.g., potatoes vs. milk, vs. pretzels, vs. tissue paper, etc.) based upon how frequently they are ordered in a distribution center. Inventory types that are ordered at the slowest rate are not “replicated” over multiple pods in the distribution center. Rather, they are constrained to reside at a single pod within the distribution center. Items that are ordered somewhat more frequently than those in the slowest group are replicated in multiple pods across the distribution center. In other words, these items are separately stocked at locations on more than one pod in the distribution center. This means that a container passing through the distribution center can obtain each of the items in the second group of item types at multiple pods in the distribution center. Thus, these items do not create a bottleneck in the order fulfillment process. Inventory types in a third group, the fastest movers, are segregated from items in the first two groups. They are stored in a separate type of pod that fulfills orders even faster than the other type of pods.
    • 负载平衡技术基于在配送中心中订购的频率,分离各种库存类型(例如,土豆对牛奶,与椒盐脆饼,对薄纸等)。 以最慢速率排序的库存类型不会在配送中心的多个pod中“复制”。 相反,它们被限制在分配中心内的单个荚上。 订购量比最慢组中的产品更频繁地复制在配送中心的多个pod中。 换句话说,这些物品分开存放在配送中心多个荚的位置。 这意味着通过配送中心的集装箱可以在配送中心的多个荚中获得第二组物品类型中的每个物品。 因此,这些项目不会在订单履行过程中产生瓶颈。 第三组中最快的移动商的库存类型与前两个组中的项目分开。 它们存储在单独类型的pod中,其顺序比其他类型的pod更快。
    • 7. 发明授权
    • Pyridylcarbamoyl Indolines
    • 吡啶基氨基甲酰基吲哚啉
    • US5834494A
    • 1998-11-10
    • US717957
    • 1996-09-23
    • Peter HamGraham Elgin JonesIan Thomson Forbes
    • Peter HamGraham Elgin JonesIan Thomson Forbes
    • A61K31/42A61K31/44A61K31/4427A61K31/475A61P1/14A61P25/00A61P25/26A61P25/28A61P43/00C07D401/12C07D413/12
    • C07D401/12C07D413/12
    • Compounds of formula (I), processes for their preparation and their use in medicine are disclosed: ##STR1## wherein: P represents phenyl, a quinoline or isoquinoline residue, or a 5-membered or 6-membered aromatic heterocyclic ring containing up to three heteroatoms selected from nitrogen, oxygen or sulphur; R.sup.1 is hydrogen, C.sub.1-6 alkyl, halogen, CF.sub.3, NR.sup.7 R.sup.8 or OR.sup.9 where R.sup.7, R.sup.8 and R.sup.9 are independently hydrogen, C.sub.1-6 alkyl or arylC.sub.1-6 alkyl; R.sup.2 is hydrogen or C.sub.1-6 alkyl; R.sup.3 is C.sub.1-6 alkyl; n is 0 to 3; m is 0 to 4; and R.sup.4 groups are independently C.sub.1-6 alkyl optionally substituted by one or more halogen atoms, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, C.sub.3-6 cycloalkyl-C.sub.1-6 alkyl, C.sub.1-6 alkylthio, C.sub.3-6 cycloalkylthio, C.sub.3-6 cycloalkylC.sub.1 C.sub.6 alkylthio, halogen, nitro, CF.sub.3, OCF.sub.3, SCF.sub.3, SO.sub.2 CF.sub.3, SO.sub.2 F, formyl, C.sub.2-6 alkanoyl, cyano, optionally substituted phenyl or thienyl, NR.sup.7 R.sup.8, CONR.sup.7 R.sup.8, or OR.sup.9 where R.sup.7, R.sup.8 and R.sup.9 are as defined for R.sup.1, CO.sub.2 R.sup.10 where R.sup.10 is hydrogen or C.sub.1-6 alkyl.
    • 公开了式(I)化合物,其制备方法及其在药物中的用途:吲哚或异喹啉残基或含有至多三个选自氮,氧或硫的杂原子的5元或6元芳族杂环; R 1是氢,C 1-6烷基,卤素,CF 3,NR 7 R 8或OR 9,其中R 7,R 8和R 9独立地是氢,C 1-6烷基或芳基C 1-6烷基; R2是氢或C1-6烷基; R3是C1-6烷基; n为0〜3; m为0〜4; 并且R 4基团独立地是任选地被一个或多个卤素原子取代的C 1-6烷基,C 2-6烯基,C 2-6炔基,C 3-6环烷基,C 3-6环烷基-C 1-6烷基,C 1-6烷硫基, C 3-6环烷基C 1 -C 6烷硫基,卤素,硝基,CF 3,OCF 3,SCF 3,SO 2 CF 3,SO 2 F,甲酰基,C 2-6烷酰基,氰基,任选取代的苯基或噻吩基,NR 7 R 8,CONR 7 R 8或OR 9,其中R 7, 如R1所定义,CO 2 R 10,其中R 10是氢或C 1-6烷基。
    • 8. 发明授权
    • Amide derivatives having 5HT1D-antagonist activity
    • 具有5HT1D-拮抗剂活性的酰胺衍生物
    • US5756496A
    • 1998-05-26
    • US737660
    • 1996-11-21
    • Peter HamLaramie Mary GasterDavid Francis KingDavid Malcolm Duckworth
    • Peter HamLaramie Mary GasterDavid Francis KingDavid Malcolm Duckworth
    • A61K31/40A61K31/41A61K31/535A61K31/55A61P25/00A61P25/20A61P25/26A61P25/28A61P43/00C07D249/12C07D413/12
    • C07D413/12
    • Compound of formula (1), processes for their preparation and their use as CNS agents are disclosed, in which A is CONR where R is hydrogen or C.sub.1-6 alkyl; Q is an optionally substituted 5 to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur, R.sup.1 is hydrogen, halogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, COC.sub.1-6 -alkyl, C.sub.1-6 alkoxy, hydroxy, hydroxyC.sub.1-6 alkyl, hydroxyC.sub.1-6 alkoxy, C.sub.1-6 alkoxyC.sub.1-6 alkoxy, acyl, nitro, trifluoromethyl, cyano, SR.sup.9, SOR.sup.9, SO.sub.2 R.sup.9, SO.sub.2 NR.sup.10 R.sup.11, CO.sub.2 R.sup.10, CONR.sup.10 R.sup.11, CO.sub.2 NR.sup.10 R.sup.11, CONR.sup.10 (CH.sub.2).sub.a CO.sub.2 R.sup.11, (CH.sub.2).sub.a NR.sup.10 R.sup.11, (CH.sub.2).sub.a CONR.sup.10 R.sup.11, (CH.sub.2).sub.a NR.sup.10 COR.sup.11, (CH.sub.2).sub.a CO.sub.2 C.sub.1-6 alkyl, CO.sub.2 (CH.sub.2).sub.a OR.sup.10, NR.sup.10 R.sup.11, NR.sup.10 CO.sub.2l R.sup.11, NR.sup.10 CONR.sup.10 R.sup.11, CR.sup.10 =NOR.sup.11, CNR.sup.10 =NOR.sup.11, where R.sup.10 and R.sup.11 are independently hydrogen or C.sub.1-6 alkyl and a is 1 to 4 or R.sup.1 is an optionally substituted 5 to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur, R.sup.2 and R.sup.3 are independently hydrogen, halogen, C.sub.1-6 alkyl, C.sub.3-6 cycloaallyl, C.sub.3-6 cycloalkenyl, C.sub.1-6 alkoxy, acyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO.sub.2 R.sup.10, CONR.sup.10 R.sup.11, NR.sup.10 R.sup.11 where R.sup.10 and R.sup.11 are as defined for R.sup.1 ; R.sup.4 and R.sup.5 are independently hydrogen or C.sub.1-6 alkyl; R.sup.6 is halogen, hydroxy, C.sub.1-6 alkyl or C.sub.1-6 alkoxy; R.sup.7 and R.sup.8 are independently hydrogen, C.sub.1-6 alkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5 to 7-membered heterocyclic ring containing one or two heteroatoms selected from oxygen, nitrogen or sulphur, m is 0 to 4; and n is 0, 1 or 2.
    • PCT No.PCT / EP95 / 01890 Sec。 371日期:1996年11月21日 102(e)日期1996年11月21日PCT提交1995年5月16日PCT公布。 第WO95 / 32967号公报 日期:1995年12月7日公开了式(1)的化合物,其制备方法及其作为CNS剂的用途,其中A为CONR,其中R为氢或C 1-6烷基; Q是任选取代的含有1-3个选自氧,氮或硫的杂原子的5至7元杂环,R 1是氢,卤素,C 1-6烷基,C 3-6环烷基,COC 1-6 - 烷基,C 1-6烷氧基,羟基 ,羟基C 1-6烷基,羟基C 1-6烷氧基,C 1-6烷氧基C 1-6烷氧基,酰基,硝基,三氟甲基,氰基,SR 9,SOR 9,SO 2 R 9,SO 2 NR 10 R 11,CO 2 R 10,CONR 10 R 11,CO 2 NR 10 R 11,CONR 10(CH 2)aCO 2 R 11,(CH 2)a NR a R 11, )aCONR10R11,(CH2)aNR10COR11,(CH2)aCO2C1-6烷基,CO2(CH2)aOR10,NR10R11,NR10CO2lR11,NR10CONR10R11,CR10 = NOR11,CNR10 = NOR11,其中R10和R11独立地为氢或C1-6烷基, 1至4或R 1为任选取代的含有1至3个选自氧,氮或硫的杂原子的5至7元杂环,R 2和R 3独立地为氢,卤素,C 1-6烷基,C 3-6环烯基,C 3-6环烯基, C 1-6烷氧基,酰基,芳基,酰氧基,羟基,硝基,三氟甲基,氰基,CO 2 R 10,CONR 10 R 11,NR 10 R 11,其中R 10和R 11如对R 1所定义; R4和R5独立地是氢或C1-6烷基; R6是卤素,羟基,C1-6烷基或C1-6烷氧基; R 7和R 8独立地是氢,C 1-6烷基,芳烷基或与它们所连接的氮原子一起形成含有一个或两个选自氧,氮或硫的杂原子的任选取代的5至7元杂环,m是 0至4; n为0,1或2。